诺瓦瓦克斯 NVAX

Mr. John C. Jacobs, CAREER HIGHLIGHTS: Novavax, Inc. ;President and Chief Executive Officer (January 2023 to present) Harmony Biosciences Holdings, Inc. ;President and Chief Executive Officer and a member of the board of directors (June 2018 to January 2023) ;Executive Vice President and Chief Commercial Officer (October 2017 to June 2018) Teva Pharmaceuticals Industries Ltd ;Senior Vice President and General Manager of the Respiratory Business Unit (September 2017 to October 2017) ;Senior Vice President of Commercial Operations and Innovation of Teva, (September 2016 to September 2017) ;Vice President and General Manager of Teva's Branded Business in Canada (July 2014 to September 2016) EDUCATION: M.B.A. from the State University of New York at Binghamton ;Bachelor of Science in Business, State University of New York College at Plattsburgh.

Elaine O'Hara CAREER HIGHLIGHTS: Novavax, Inc. ;Executive Vice President, Chief Strategy Officer (March 2023 to present) Sanofi Vaccines ;Chief Commercial Officer (2017 to March 2023) Otsuka America Pharmaceuticals, Inc. ;Senior Vice President, Commercial Operations (2012 to 2017) Pfizer Pharmaceuticals ;Anti-Infective Portfolio Commercial Lead - U.S. Specialty Care (2012) ;Senior Director / Team Lead - U.S. Zyvox (2010 to 2011). EDUCATION: M.B.A., HAUB School of Business Saint Joseph's University ;Bachelor of Arts, National University of Ireland.

James P. Kelly CAREER HIGHLIGHTS: Novavax, Inc. ;Executive Vice President, Chief Financial Officer and Treasurer (August 2021 to present) Supernus Pharmaceuticals ;Executive Vice President, Chief Financial Officer (October 2020 to August 2021) Vanda Pharmaceuticals Inc. ;Executive Vice President, Chief Financial Officer and Treasurer (February 2017 to March 2020) ;Senior Vice President, Chief Financial Officer and Treasurer (December 2010 to February 2017) MedImmune, LLC ;Vice President and Controller. EDUCATION: M.B.A., Cornell University ;Bachelor of Science in Business, University of Vermont.

JOHN W. SHIVER, PH.D. CAREER HIGHLIGHTS: Vibrant Biomedicines ;Head of Research and Development (2024 to present) F-Prime Capital ;Special Advisor (2021 to present) University of Pennsylvania ;Adjunct Professor, College of Medicine (2008 to present) IGM ID ;Chief Strategy Officer, Infectious Disease Business Unit (2021 to 2023) Sanofi Pasteur ;Senior Vice President (2013 to 2020) Merck & Co., Inc. ;Vice President, Vaccine Basic Research & Franchise Head (2007 to 2013) ;Vice President, Vaccines & Biologics Research (2004 to 2007) ;Executive Director, Vaccines Research (1991 to 2004). OTHER CURRENT DIRECTORSHIPS ;Calder Biosciences ;AuraVax Therapeutics. EDUCATION: Ph.D. in Physical Chemistry, University of Florida ;Bachelor of Science in Chemistry and Mathematics, Wofford College.

CHARLES W. NEWTON CAREER HIGHLIGHTS: Lyell Immunopharma, Inc. Chief Financial Officer (2021 to 2025) Bank of America Managing Director & Co-Head of Healthcare Investment Banking in the Americas (2015 to 2021) Credit Suisse Managing Director, Co-Head of Healthcare Investment Banking in the Americas (2010 to 2015) Morgan Stanley Managing Director and Head of Western Region Healthcare Investment Banking (June 1996 to September 2010). OTHER CURRENT DIRECTORSHIPS: Coherus Oncology (Nasdaq: CHRS) Keros Therapeutics, Inc. (Nasdaq: KROS). EDUCATION: M.B.A., The Tuck School of Business at Dartmouth College Bachelor of Science in Finance, Miami University.

MARGARET G. MCGLYNN, R.Ph. CAREER HIGHLIGHTS: International AIDS Vaccine Initiative ;President and Chief Executive Officer, leading extensive partnership efforts to advance the development, global launch and access to a broadly effective HIV vaccine (2011 to 2015) Merck Served in leadership roles of increasing responsibility for more than two decades (1983 to 2009) including: ;President, U.S. Hospital and Specialty Products Division ;President of Merck Vaccines and Infectious Diseases OTHER PUBLIC COMPANY BOARDS ;Amicus Therapeutics (Nasdaq: FOLD) OTHER CURRENT DIRECTORSHIPS : University at Buffalo Foundation. EDUCATION: Honorary Doctorate, the State University of New York at Buffalo ;Master's in Business Administration and Marketing, The State University of New York at Buffalo ;Bachelor of Science in Pharmacy, The State University of New York at Buffalo.

Mr. Richard J. Rodgers, CAREER HIGHLIGHTS : TESARO, Inc. ;Former Co-Founder, Executive Vice President, Chief Financial Officer, Secretary, and Treasurer (2010 to 2013) ;Mr. Rodgers guided TESARO, Inc. through an acquisition by GSK for over $5 billion Abraxis BioScience, inc. ;Chief Financial Officer and Senior Vice President of Abraxis BioScience, Inc. (2009 to 2010) ;Mr. Rodgers guided Abraxis BioScience, Inc. through an acquisition by Celgene for $2.9 billion MGI PHARMA, Inc. ;Senior Vice President, Controller and Chief Accounting Officer of MGI PHARMA, Inc. ;Helped guide MGI PHARMA, Inc. through an acquisition by Eisai for $3.9 billion. OTHER PUBLIC COMPANY BOARDS: Ardelyx, Inc. (Nasdaq: ARDX) ;Opus Genetics, Inc. (Nasdaq: IRD) EDUCATION: Bachelor of Science in Financial Accounting, St. Cloud State University ;M.B.A., University of Minnesota, Carlson School of Business.

DAVID MOTT CAREER HIGHLIGHTS: Sphinx Mountain Capital LLC Chief Executive Officer and Chief Investment Officer (2025 to present) Mott Family Capital Private investor (2020 to 2025) New Enterprise Associates General Partner (2008 to 2020) MedImmune President and Chief Executive Officer, Vice Chairman (2000 to 2008), during which he led the sale of the company to AstraZeneca in June 2007 for $15.6 billion Served in various senior roles, including Chief Operating Officer and Chief Financial Officer (1992 to 2000) OTHER PUBLIC COMPANY BOARDS: Chairman, Ardelyx (Nasdaq: ARDX). EDUCATION: Bachelor of Arts, Dartmouth College.

RICHARD H. DOUGLAS, PH.D. CAREER HIGHLIGHT : Genzyme Corporation ;Former Senior Vice President, Corporate Development (1989 to 2011) ;Dr. Douglas led Genzyme Corporation's Corporate Development team, and was involved in numerous acquisitions, licenses, financings, joint ventures, and strategic alliances Integrated Genetics ;Dr. Douglas served in science and corporate development capacities (1982 until its merger with Genzyme Corporation in 1989, now Sanofi Genzyme) OTHER PUBLIC COMPANY BOARDS ;Alderya Therapeutics, Inc. (Nasdaq: ALDX) ;MaxCyte, Inc. (Nasdaq: MXCT). OTHER CURRENT DIRECTORSHIPS : University of Michigan Innovation Partnerships National Advisory Board EDUCATION : Postdoctoral fellow, Dr. Leroy Hood's laboratory at the California Institute of Technology ;Ph.D. in Biochemistry, University of California, Berkeley ;Bachelor of Science in Chemistry, University of Michigan.

RACHEL K. KING CAREER HIGHLIGHTS: The Biotechnology Innovation Organization ;Interim Chief Executive Officer (2022 to 2024) GlycoMimetics, Inc. ;Founder and former Chief Executive Officer (2003 to 2021) New Enterprise Associates ;Executive in Residence (2001 to 2003) Novartis Corporation ;Senior Vice President (1999 to 2001) Genetic Therapy, Inc. ;Chief Executive Officer of GTI, a wholly owned subsidiary of Novartis (1996 to 1998) ;Vice President for Product Planning (1993 to 1996) including early-stage development, initial public offering and acquisition by Novartis ;Manager of Laboratory Operations (1989 to 1993). OTHER CURRENT PUBLIC COMPANY BOARDS ;Fulcrum Therapeutics (Nasdaq: FULC). OTHER CURRENT DIRECTORSHIPS: Biotechnology Innovation Organization ;University of Maryland BioPark ;Maryland Life Sciences Advisory. EDUCATION: M.B.A., Harvard Business School ;Bachelor of Arts, Dartmouth College.

Robert Walker, M.D. CAREER HIGHLIGHTS: Novavax, Inc. Executive Vice President, Head of Research & Development (March 2026 to present) Senior Vice President and Chief Medical Officer (April 2023 to March 2026) Senior Vice President and Deputy Chief Medical Officer (August 2022 to March 2023) Meissa Vaccines Chief Medical Officer (July 2021 to April 2022) Biomedical Advanced Research and Development Authority (BARDA) Chief Medical Officer and Director, Division of Clinical Development (October 2015 to July 2021) Deputy Director, Division of Clinical Studies (July 2014 to October 2015) Nuron Biotech Inc. Chief Medical Officer (January 2013 to June 2014). EDUCATION : Hospital of the University of Pennsylvania, Fellowship, Pulmonary and Critical Care Medicine George Washington University Medical Center, Residency, Internal Medicine University of Maryland School of Medicine, Doctor of Medicine (M.D.), Medicine Vassar College, Bachelor of Arts, BA.